OptiNose (OPTN) Stock Price, News & Analysis

Company Overview

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Key Stats

• Today's Range: $9.25 to $9.35
• 50-Day Range: $5.27 to $9.34
• 52-Week Range: $4.82 to $20.03
• Volume: 25,408 shs
• Average Volume: 61,483 shs
• Market Capitalization: $94.59 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Hold

OptiNose Stock Analysis - MarketRank™

OptiNose scored higher than 66% of companies evaluated by MarketBeat, and ranked 446th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

OptiNose has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

OptiNose has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for OptiNose are expected to grow in the coming year, from ($3.22) to ($2.82) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of OptiNose is -2.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of OptiNose is -2.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.80% of the float of OptiNose has been sold short.

Short Interest Ratio / Days to Cover

OptiNose has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in OptiNose has recently decreased by 25.82%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OptiNose does not currently pay a dividend.

Dividend Growth

OptiNose does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -2.10

Percentage of Shares Shorted

1.80% of the float of OptiNose has been sold short.

Short Interest Ratio / Days to Cover

OptiNose has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in OptiNose has recently decreased by 25.82%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.57

News Sentiment

OptiNose has a news sentiment score of 1.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for OptiNose this week, compared to 2 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, OptiNose insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $43,643.00 in company stock.

Percentage Held by Insiders

Only 2.30% of the stock of OptiNose is held by insiders.

Percentage Held by Institutions

85.60% of the stock of OptiNose is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OPTN Stock Analysis - Frequently Asked Questions

How have OPTN shares performed this year?

OptiNose's stock was trading at $6.68 at the beginning of the year. Since then, OPTN shares have increased by 39.8% and is now trading at $9.34.
View the best growth stocks for 2025 here.

How were OptiNose's earnings last quarter?

OptiNose, Inc. (NASDAQ:OPTN) announced its earnings results on Wednesday, March, 26th. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.70) by $0.67. The business had revenue of $21.47 million for the quarter, compared to the consensus estimate of $21.02 million.

When did OptiNose's stock split?

OptiNose's stock reverse split on Tuesday, December 31st 2024. The 1-15 reverse split was announced on Thursday, December 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, December 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did OptiNose IPO?

OptiNose (OPTN) raised $101 million in an initial public offering (IPO) on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO.

Who are OptiNose's major shareholders?

Top institutional investors of OptiNose include Deltec Asset Management LLC (0.22%) and FNY Investment Advisers LLC (0.04%). Insiders that own company stock include Ramy A Mahmoud, Peter K Miller, Michael F Marino III, Paul Jr Spence, Anthony J Krick and Michele Janis.
View institutional ownership trends.

How do I buy shares of OptiNose?

Shares of OPTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of OptiNose own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OptiNose investors own include NVIDIA (NVDA), CymaBay Therapeutics (CBAY), GE Aerospace (GE), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET) and Adobe (ADBE).

Company Calendar

• Last Earnings: 3/26/2025
• Today: 4/29/2025
• Next Earnings (Estimated): 5/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OPTN
• CIK: 1494650
• Web: www.optinose.com
• Phone: (267) 364-3500
• Fax: N/A
• Employees: 190
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.00
• High Stock Price Target: $9.00
• Low Stock Price Target: $9.00
• Potential Upside/Downside: -3.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-35,480,000.00
• Net Margins: -41.16%
• Pretax Margin: -41.16%
• Return on Equity: N/A
• Return on Assets: -27.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.79
• Quick Ratio: 0.72

Sales & Book Value

• Annual Sales: $78.23 million
• Price / Sales: 1.21
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($11.56) per share
• Price / Book: -0.81

Miscellaneous

• Outstanding Shares: 10,127,000
• Free Float: 9,829,000
• Market Cap: $94.59 million
• Optionable: Not Optionable
• Beta: -0.87